MCX launches Cardamom Futures Contracts to strengthen spice market ecosystem
Initially, contracts will be available for expiry in August, September, October, and November 2025. Trading for these will run from Monday to Friday, between 9:00 AM and 5:00 PM. Each contract will represent 100 kilograms of cardamom and be quoted in rupees per kilogram, with the benchmark pricing based on the ex-Vandanmedu (in Kerala's Idukki district) rate.
This is a compulsory delivery contract, which means physical delivery of cardamom is involved at the end of the contract period. To manage volatility, a daily price limit of 4% will be in place. If this limit is hit, trading will pause for 15 minutes, after which an additional 2% band may be allowed. Margins start at a minimum of 10% or as required by SPAN, along with a fixed 1% Extreme Loss Margin.
With this launch, MCX is offering a structured platform that could help formalize spice trading further and give stakeholders—especially smaller farmers—better access to national markets.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions
Former FDA Director David Feigal joins Keyron as Head of Regulatory Affairs Dr Joyce Peetermans (ex-Boston Scientific) joins as Acting CTO Christopher Rowland (ex-Boston Scientific) appointed Chairman ForePass aims to replicate metabolic surgery without incisions Preparing for First-In-Human trials after strong large-animal data Head-to-head data showing superiority over $28B/year drug to be published soon LONDON & BOSTON, August 06, 2025--(BUSINESS WIRE)--Keyron, a pioneer in medical devices for advanced metabolic disease, today announced the appointment of three world-class leaders to its board of directors—including the former Director of the FDA's Center for Devices and Radiological Health (CDRH) and senior medtech industry leaders with key roles in notable exits within the endoscopy medical device sector. These appointments strengthen Keyron's regulatory, clinical, and strategic leadership as the company prepares for its upcoming clinical trials, associated global regulatory submissions, and future strategic alliances, centered around its ForePass device. ForePass is designed to replicate the outcomes of metabolic surgery—without cutting, puncturing, or trauma—through a fully reversible, minimally invasive procedure. Board Appointments David Feigal MD (Head of Regulatory Affairs) – Former Director of the FDA's Center for Devices and Radiological Health (CDRH). Covered the highest role and authority in medical devices at the FDA. Brings decades of experience guiding breakthrough technologies through FDA approval and will now be the Company's lead for FDA engagement and IDE submission. Founder of leading U.S. regulatory consultancy, NDA Partners. Widely recognized as one of the most experienced regulatory experts in the U.S., he has held senior global roles at public companies Amgen and Elan and led or advised over 20 successful medical product approvals across therapeutic areas. Joyce Peetermans, Ph.D. (Acting CTO) – 35+ years of leadership roles in R&D, Clinical Research, and Innovation in Gastroenterological and Surgical Endoscopy, and other specialties. She spent 25 years at Boston Scientific, where she was on the Endoscopy Management Board as VP of Global Clinical Programs, and VP of Innovation and Research during the $615M acquisition of Apollo Endosurgery and several other key acquisitions by Boston Scientific Endoscopy. Christopher Rowland (Chairman) – A seasoned executive with over 35 years leading Class III endoscopic and metabolic device companies. He served as President at Given Imaging prior to its $860M PillCam exit to Covidien (Medtronic) and was CEO of Neotract before its $1.1B acquisition by Teleflex. He also spent 17 years in senior roles at Boston Scientific. Christopher will chair Keyron's board of directors and support its corporate development and fundraising strategy. This leadership expansion follows several successful large-animal studies of ForePass demonstrating excellent safety, tolerability, and strong efficacy on both weight and insulin production. Key results were published in Gut (Angelini G, Galvao Neto M, Boskoski I, et al., 2024), showing ForePass's ability to replicate surgery-like results without incisions. The company is now preparing to unveil best-in-class preclinical data showing clear superiority over Semaglutide—the $28B/year standard of care for obesity and diabetes in Ozempic and Wegovy—across all major endpoints. These data are expected to be published this summer. 92% of Semaglutide patients fail to achieve 15% total body weight loss (New England Journal of Medicine, 2021; 385(6):503–515), with 85% discontinuing GLP-1 therapy within just 24 months (Reuters, 10 July 2024). Yet patients with severe obesity (BMI ≥35)—especially those who also have type 2 diabetes—need around 30% weight loss. Since GLP-1s fall substantially short and most stop taking them, surgery remains the only viable option, regularly delivering over 30% weight loss despite its risks and complications. ForePass is a fully removable, endoscopically implantable device aiming to replicate the metabolic benefits of surgery without incisions. It targets patients with BMI ≥35 and diabetes or BMI ≥40—a large, high-risk population underserved by current treatments. Giorgio Castagneto Gissey, Founder & CEO of Keyron, said: "Christopher, David, and Joyce are absolute world-class leaders. Their decision to join Keyron reflects the urgency of the metabolic crisis—especially the unmet need in diabetes and higher BMI—and the unique power of what we've built. Their expertise will be transformative as we enter human trials and deliver the first truly effective, scalable alternative to surgery for millions." Keyron, a VC-backed startup, has developed a proprietary biometabolic implant and endoscopic delivery system, secured leading clinical sites in the U.S. and internationally, and completed long-term preclinical validation. Full efficacy results—including head-to-head data versus Semaglutide in a porcine model—will be published shortly. The company is now preparing for its First-In-Human study. About Keyron Keyron is the first biometabolic device platform company, pioneering a new class of implantable therapies that aim to replicate the effects of bariatric and metabolic surgery without incisions—and restore metabolic health at its root without driving insulin overproduction or dependency. Headquartered in London and Boston, Keyron's mission is to deliver a scalable alternative to surgery—and a better option for patients with severe obesity and diabetes. See for more information. View source version on Contacts Media Contact Keyron Press Officepress@ London, UK and Boston, MA Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
14 hours ago
- Business Upturn
HUDCO Q1 Results: Net profit jump 13% YoY to Rs 630.2 crore, NII up 11.2% YoY
HUDCO released its Q1 FY26 results for the quarter ended June 30, 2025, reporting a solid financial performance with year-on-year growth across key metrics. Revenue from operations stood at ₹2,937.31 crore, compared to ₹2,188.35 crore in Q1 FY25, showing a year-on-year increase of 34.23%. Total income, including other income, rose to ₹2,945.47 crore from ₹2,197.19 crore, up 34.06%. Net interest income (NII) for the quarter came in at ₹961 crore, compared to ₹724.7 crore in the same quarter last year, up 11.2%. Profit before tax stood at ₹857.23 crore, up from ₹684.70 crore, showing a growth of 25.22% year-on-year. Net profit for the quarter was ₹630.2 crore compared to ₹558 crore in Q1 FY25, an increase of 13%. EBITDA for the quarter stood at ₹2,828.32 crore, rising 32% from ₹2,141.51 crore in Q1 FY25. EBITDA margin came in at 96.3%, slightly lower than 97.9% in the previous year. On the asset quality front, the gross NPA ratio improved to 1.34% from 2.42% in Q1 FY25, while net NPA dropped to 0.09% from 0.33% a year earlier. The company also declared its first interim dividend for the financial year 2025–26. A dividend of ₹1.15 per equity share (i.e., 11.50% on the face value of ₹10 per share) has been approved, subject to deduction of TDS. The record date for determining the eligibility of shareholders for receiving this dividend has been fixed as Thursday, 14th August 2025. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
16 hours ago
- Business Upturn
Infosys launches advanced AI, cybersecurity and space tech center in Hubballi, Karnataka
Infosys, a global leader in digital services and consulting, has announced the launch of its cutting-edge Infosys Center for Advanced AI, Cybersecurity, and Space Technology at its Hubballi Development Center (DC) in Karnataka. This latest initiative underscores Infosys' commitment to strengthening its innovation ecosystem while positioning Hubballi as a rising technology hub in India. The new center is part of the global 'Infosys Living Labs' network, which comprises over 12 centers worldwide. These labs are designed to help businesses fast-track innovation and embrace emerging technologies such as artificial intelligence, cloud computing, cybersecurity, engineering services, SAP, and space technology. The Hubballi facility will play a strategic role in delivering digital-first solutions to clients across key industries including manufacturing, financial services, retail, and healthcare. With more than 1,000 employees currently working at the Hubballi DC, Infosys continues to focus on nurturing local talent and building future-ready capabilities. The company has also partnered with institutions like IIIT Dharwad and KLE Tech, fostering strong industry-academia collaboration aimed at research, innovation, and skill development in the region. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
